MRVI vs. MRNA

In the year-to-date period, MRVI achieves a -58.72% return, which is significantly lower than MRNA's -36.12% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Maravai LifeSciences Holdings, Inc. (MRVI) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current MRVI Sharpe Ratio is -0.91, which is comparable to the MRNA Sharpe Ratio of -1.21. The chart below compares the historical Sharpe Ratios of MRVI and MRNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither MRVI nor MRNA has paid dividends to shareholders.

The maximum MRVI drawdown since its inception was -97.16%, roughly equal to the maximum MRNA drawdown of -95.12%. Use the drawdown chart below to compare losses from any high point for MRVI and MRNA.

The current volatility for Maravai LifeSciences Holdings, Inc. (MRVI) is 21.20%, while Moderna, Inc. (MRNA) has a volatility of 22.45%. This indicates that MRVI experiences smaller price fluctuations and is considered to be less risky than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Maravai LifeSciences Holdings, Inc. and Moderna, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.